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THE VALIDITY OF SMARTPHONE DATA AND ITS RELATIONSHIP TO 
CLINICAL SYMPTOMATOLOGY AND BRAIN BIOLOGY: AN 
EXPLORATORY ANALYSIS 
CONOR RIZZUTO 
ABSTRACT 
Background: Presently, there is very little research on the clinical validity of mental health 
smartphone application data, its relationship to brain biology, and its ability to inform 
clinical decisions. This paper seeks to explore these relationships within a sample of 
schizophrenic patients through the analysis of data collected on the mental health 
smartphone application Biewe. 
Objectives: To validate mental health smartphone applications and support their potential 
to augment clinical practice.  
Methods: The application involved a series of 21 questions from several questionnaires 
including Patient Health Questionnaire-8 (PHQ-8), Generalized Anxiety Disorder-7 
(GAD-7), Warning Signals Scale (WSS), Pittsburgh Sleep Quality Index, and the 
psychosis subscale of the Mini Mental State Examination. Data was collected over a 
period of 3 months, and patients attended a total of 4 clinic visits during this timeframe. 
Seven study participants also had brain scan data available from the BSNIP, PARDIP and 
Biceps studies currently in progress at MMHC which has been used for analysis. The 
structural MPRAGE T1 scans were processed using Free Surfer 6 in which thickness and 
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volume measures were extracted. All statistical analyses on the data were carried out 
using R statistics software.   
Results: Clinic and application responses within the same week were not significantly 
different from each other. The application answers, however, appeared to be more sensitive 
to structural abnormalities in the brain. Symptoms defined as a lack of normal emotional 
responses (i.e. negative symptoms of schizophrenia) were negatively correlated to home 
time and positively correlated to distance travelled, which was a counterintuitive result.  
Conclusions: The results show that mobile monitoring has the potential to be a valid and 
reliable method of data collection and that it may be able to augment clinical decision 
making.  
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INTRODUCTION 
 To date, there exists limited literature on the use of smartphone applications to 
assess and monitor mental health symptoms. With global smartphone application 
ownership cited at 25% worldwide by 2015, and 65% in the US, mobile monitoring of 
mental health symptoms has the potential to become a powerful tool in the clinical 
toolbox (Firth et al, 2015). Clinic interview scales are currently the gold standard method 
of assessing symptoms but cross sectional data presents several limitations, such as recall 
bias and interrater reliability. Mobile monitoring could be a solution to these issues by 
painting a longitudinal picture of a disease state, but it needs to be shown that this data is 
valid, and that the method of collection is safe and feasible (Palmier-Claus et al, 2012).  
 Of the studies that have employed the use of smartphone applications to collect 
data on symptoms, many have reported high satisfaction with this medium. A study 
involving patients with head and neck cancer demonstrated that substantial symptom 
reporting is possible using mobile device technology (Falchook et al, 2016), a conclusion 
gleaned from the impressive participation in the study (median report compliance of 
~71%). Additionally, there has been investigation into the utility of smartphone 
applications within various branches of medicine. A study in 2016 involving an 
application called Pain Buddy was aimed at pain assessment and management in children 
with cancer. Several key features included daily symptom diaries, cognitive and 
behavioral skills training and interactive three-dimensional avatars that guided children 
through the program (Fortier et al, 2016). Another study discussed the use of a smart 
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phone application to help patients manage their chronic kidney disease, and in an exit 
interview patients reported they felt more confident and in control of their condition (Ong 
et al, 2016).  
 The branch of medicine that can also benefit from this kind of innovation is 
psychiatry. Mental illness puts a huge burden on the individual and the economy, and yet 
there is significant unmet need in the population. It is cited that only about 25% of 
persons with mental health problems currently receive adequate professional help 
(Beiwinkel et al, 2017). It is therefore imperative that steps are taken to improve this 
statistic. This study recruited patients with a diagnosis of schizophrenia. Schizophrenia is 
a mental illness occurring in about 1% of the population and is characterized by psychotic 
symptoms, cognitive impairment and functional decline. While a plethora of research has 
been done on schizophrenia, much of the disease state including its etiology remains 
unknown (Feigenson et al, 2014). The generally agreed upon central dichotomy of 
symptoms present in patients with schizophrenia is the distinction between positive and 
negative symptoms. Positive symptoms are defined as hallucinations, delusions, 
disorganized thoughts and behavior and related aggression (Carbon et al, 2014). Negative 
symptoms are defined as a lack of normal emotional responses, thought processes and 
behaviors and include flat affect, apathy, anhedonia and poor concentration. These 
symptoms contribute to poor long term outcomes through a reduction of quality of life 
and increased burden of illness (Chue et al, 2014). It has been strongly suggested that the 
anterior cingulate cortex is implicated in the pathogenesis of schizophrenia, and more 
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specifically, with the negative symptoms of schizophrenia. Negative symptom 
comparisons in this study were therefore focused on this region. Studies have also shown 
correlations between positive symptoms and gray matter volume abnormalities in the 
caudate, corpus callosum, fusiform gyrus and to overall gray matter. These volumes were 
the focus of the positive symptom comparisons.  
Schizophrenia is a serious mental illness that is often hard to find adequate care 
for. Symptoms usually present in early adulthood or late adolescence and males tend to 
have a worse prognosis, including more negative symptoms and less chance of a full 
recovery. A systematic review of studies on schizophrenia has determined that patients 
with schizophrenia have smaller whole brain volumes, with the greatest impact on grey 
matter in the frontal and temporal lobes. Additionally, 80% of patients recover after their 
first episode, but less than 20% of those patients will never have a recurrent episode 
(Picchioni et al, 2007). Furthermore, a study by Emsley et al (2013) stated that multiple 
relapses characterize the course of illness for most patients living with schizophrenia, but 
the nature of these relapses has not be extensively researched. In addition to general 
assessment and management of symptoms, it is the hope that mobile data will eventually 
help us learn when patients are at their highest risk of a relapse.   
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                                                        SPECIFIC AIMS 
In a previous study on patients with schizophrenia where smartphone and in 
person clinic responses were compared, 5 items showed moderate to strong associations 
to corresponding items from interview scales. These items included delusions, 
hallucinations, suspiciousness, anxiety and hopelessness (Palmier-Claus et al, 2012). A 
similar goal was sought to be achieved in this study.  
The primary goals of the study were to assess overall engagement with a 
symptom reporting application, to determine whether responses were consistent across 
application and clinic (i.e. there was no evidence of a tendency for under or over 
reporting), to introduce passive measures as a useful future digital biomarker, to evaluate 
the sensitivity of the application and clinic scales to structural abnormalities in the brain 
and finally, to provide a case for the integration of mobile monitoring into the world of 
mental healthcare.   
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 METHODS  
Data Collection 
 
 The sample included schizophrenia patients (n = 19), 15 of whom participated in 
the smartphone side of the study. The application involved a series of 21 questions from 
several questionnaires including PHQ-8, GAD-7, Warning Signals Scale (WSS), 
Pittsburgh Sleep Quality Index, and the psychosis subscale of the MINI. The scales on 
the former four questionnaires were 0-3, while the psychosis subscale is in the format of 
“Yes” or “No” answers. These were recorded as “0” for “No” and “1” for yes.  The 
application prompted participants to answer 7 questions a day every Monday, Wednesday 
and Friday of each week so that at the end of each week they had answered all 21 
questions. All participants were given the option to postpone surveys for up to two days 
after they were first presented. This survey data is referred to throughout the text as 
“active data” to make the distinction between survey answers and “passive data”. Passive 
data was collected on the Biewe application through smartphone GPS data and was 
collected during the entirety of the 3-month study as long as the patient’s phone was on. 
The passive measures of interest were home time, significant locations visited, distance 
travelled, outgoing and incoming texts (Table 1). Participants were asked to attend a total 
of 4 clinic visits spaced 1 month apart during this timeframe. Each patient’s first clinic 
visit acted as a baseline where they were taught how to set up the application and how to 
use it. At each visit, they were also asked to complete the PHQ -8, GAD7, Warning 
Signals Scale (WSS), Pittsburgh Sleep Quality Index, and the psychosis subscale of the 
   
6 
 
MINI. Seven study participants also had brain scan data available from the BSNIP, 
PARDIP and Biceps studies currently in progress at MMHC which was used for 
analyses. The structural MP RAGE T1 scans were processed using Free Surfer 6, an open 
source software suite for processing and analyzing brain MRI images, in which thickness 
and volume measures were extracted.  
Table 1. Passive Measures. Descriptions of the passive measures of interest in this study, 
derived from the work done by Canzian et al (2015).  
 
Passive 
Measure  
                Description                Method of Calculation 
 
Distance 
Travelled  
Total distance covered each day 
over the course of the study, where 
d(Ci + Ci + 1) is the geodesic distance 
between the latitude-longitude 
pairs Ci and Ci+1. Units are arbitrary. 
 
𝑁𝑠𝑖𝑔(𝑡1, 𝑡2) =  ∑ 𝑑(𝐶𝑖, 𝐶𝑖+1)
𝑁(𝑡1,𝑡2)
𝑖=1
 
 
 
 
Home 
Time  
"Home" is defined as the cluster in 
which the user is found most often 
at 02:00, 06:00 and 20:30 on 
weekdays. Therefore, home time is 
calculated as the time intervals in 
which the participant is present at 
the coordinates CH, of this cluster. 
 
 
 
𝐻𝑡 =  ∑ 𝑡(𝐶𝐻) given in minutes/day 
Significant 
Locations 
Visited  
 
"Significant Location" is assigned to 
the 10 most visited places among all 
places visited by the user in the 
time period of the study. 
 
𝑁𝑠𝑖𝑔(𝑡1, 𝑡2) =  ∑ 𝑚𝑖𝑛 { ∑ 1𝑖𝑠𝑗, 1
𝑁(𝑡1,𝑡2)
𝑖=1
}
10
𝑗=1
 
 
 
Outgoing 
Texts 
 
Total texts sent each day over the 
course of the study. 
 
Direct data retrieval from database. Apple 
phones do not allow this. 
 
Incoming 
Texts 
 
Total texts received each day over 
the course of the study. 
 
Direct data retrieval from database. Apple 
phones do not allow this. 
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Survey Participation 
 
To approximate total participation, the total time each participant was present in 
the study was used to determine the maximum number of surveys we know were 
presented to the patient, and the actual number of surveys taken was divided by this 
number. Each patient then had a survey participation rate percentage that was used for a 
correlation analysis. The main passive metric that was of interest here was home time in 
minutes, with a hypothesis that patients would be more active on their phones the more 
they stayed home. The participation rates were then split into two groups based on phone 
type (Android vs. Apple), and total participation rates for each were determined.  
 
Fisher’s Exact Tests 
Fisher’s Exact was used over a chi square analysis due to the small sample size 
and the resulting small number of observations for each rating (i.e. some observations 
were 0). Eight out of the 21 questions available on the application that were the most 
comparable (similar to identical) to the clinic questions were chosen as a basis for 
comparison to determine whether there was a significant difference in symptom reporting 
on the application vs. the gold standard clinical scales. There were 19 patients in the 
study, and only 15 had active data recorded on the application. One of those 15 patients 
was removed due to a lack of responses in close proximity (+/- 3 days) to the clinic dates. 
The tests included responses from a total of 47 clinic visits and 69 application answers 
within the same week as the clinic visits (+/- 3 days from each clinic visit). Because the 
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study group included both Apple and Android software, phone type was used as a 
covariate in the Fisher analysis by separating the analysis into two groups. Gender was 
not considered due to the very uneven distribution in this study. The tests were carried 
out using the function “fisher.test” in R Studio.  
 
Repeated Measures Correlations 
 Repeated measures correlations are used to determine the common within-
individual association for paired measures assessed on two or more occasions for 
multiple individuals (Bakdash et al, 2017). The passive data totaled over 1700 entries, 
and because each measure was assessed on multiple occasions for each patient, it was 
decided that this was an appropriate statistical technique to use. For this analysis, passive 
measures home time, distance travelled, significant locations visited, outgoing texts and 
incoming texts were looked at. Only data from Android users was used due to the data 
collection restrictions that Apple has enforced. To carry out the analysis, the package 
“rmcorr” was installed into base R Studio. Results were adjusted for multiple 
comparisons with the false discovery rate, which is a method of controlling for type 1 
errors, or false positives, when hypothesis testing with multiple comparisons.
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Correlation Coefficient  
 Pearson’s correlations were performed in the analysis of the Biewe data set 
through the package “Hmisc” with the function “rcorr”. Upon examining the histograms 
of the passive data used in these correlations, distance travelled appeared logarithmic, 
thus a log transformation was performed with R Studio prior to running the correlations 
to make the data more uniform and to aid in any linear associations. The data was then 
adjusted with the false discovery rate. No covariates were included due to the extremely 
small sample size, but the possibilities included age, race, scanner type and phone type. 
The effect of gender would have likely been negligible because only one female used the 
smartphone application.  
 
Symptom Scores 
 Positive and negative symptom scores were determined for each patient with 
brain scans by grouping several symptom responses and averaging these responses over 
the course of the study to account for short term fluctuations. The negative symptom 
score on the application included the responses from the following symptoms: little 
interest or pleasure in things, trouble concentrating and withdrawing from social 
interaction. The negative symptom score for the clinic included a lack of enthusiasm in 
doing things, trouble concentrating, unable to concentrate, and lack of interest in things.  
The positive symptom score for the application was a combination of difficulty thinking 
clearly, feeling confused or puzzled, feeling suspicious and hearing voices or seeing 
things. The symptoms included in the clinic positive symptom score were feeling 
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confused, feeling paranoid now, external locus of control now, special messages now, 
strange beliefs now, hearing voices now and having visions now. The scores were then 
correlated with the volumes of brain structures that have been reported in the literature to 
be involved in schizophrenia. Of note, the psychosis subscale of the MINI includes 
“Now” and “Ever” versions of these questions. Only the “Now” versions were considered 
useful in this analysis.  
 
Plots and Tables 
 The stacked column graph was generated with the R Studio package “ggplot2” 
and with the function “ggplot”. The eight symptoms were identical to the ones used in the 
Fisher’s exact tests. Most of the tables were generated with the package “FlexTables” in 
R Studio with the function “vanilla.table”. The demographic table was created in Excel.  
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  RESULTS 
 
 Overall, the study recruited 19 participants with a diagnosis of schizophrenia. 
Only 15 of those patients participated in the application side of the study and of those 15, 
7 had brain scans available from parallel studies. There were only 2 females in the study, 
the rest identifying as male. The two phone types represented in the study were Apple 
and Android. The two types of scanners used for Magnetic Resonance Imaging were 
MR750 and Siemens. This information is summarized in Table 2.  
  
A longitudinal display of the study was created with stacked columns to capture 
the entirety of the study by week, and to show the contrast between one patient who was 
very active in reporting their symptoms versus one patient who was not. The stacked 
column display in Figure 1 is color coded by symptom and the x axis is in a week – 
year format, with clinic visits labeled.  
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Table 2. Demographics of the Study. This table of characteristics shows the number of 
participants that belong to each category and the percent of the total participants that this 
category represents. The scanner section only applies to the 7 patients with brain scan data 
available.  
 
Characteristic                    Number        Percent 
Age                             
20-29                           14 74% 
30-39                            4 21% 
40-43                            1 5% 
 
Gender 
  
Female 2 12% 
Male 17 88% 
 
Race 
  
Caucasian 8 42% 
African American 3 16% 
Hispanic 4 21% 
East African 2 11% 
East Asian 1 5% 
Caribbean  1 5% 
 
Phone Type 
  
Apple  8 42% 
Android  11 58% 
 
Scanner 
  
MR750 4 57% 
Siemens 3 43% 
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Figure 1. A Longitudinal Display of the Study. This figure is a longitudinal stacked column 
display of the study with the responses of two patients to seven different symptoms over the 
course of the study. The title of each plot shows the subject ID’s of both patients to preserve 
anonymity. The height of each colored bar corresponds to the severity of the symptom during the 
week the survey was taken, on a scale of 0-3. 
 
 
A total survey completion rate of 57% was determined for Android users and 49% 
for Apple users. Regressing survey participation rate and the passive measure of home 
time in minutes yielded a positive correlation with an R2 of 0.22. This is shown in Figure 
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2 below. 
 
Figure 2: Home Time vs. Survey Participation Rate. A scatter plot using the average 
participation rates for the application vs. average home time measured in minutes.  
 
To determine if there were any significant differences in the way symptoms were 
reported on the application vs. the clinic visits, Fisher’s exact tests were performed on the 
frequencies of 8 of the 21 symptoms. The application responses used were within +/- 3 
days of the clinic visit responses. Responses were measured with and without controlling 
for phone type. There were no significant findings in this analysis. The findings are 
separated into three tables below. Table 3 includes both phone types, Table 4 shows only 
Apple users, and Table 5 only Android users.  
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Table 3. Total Fisher’s Exact Analysis. The Fisher’s exact p values generated after comparing 
the responses to 8 different symptoms (on a scale of 0 to 3, 3 being the most severe) in clinic and 
on the application within +/- 3 days of each other. The times each question was answered in clinic 
is constant for each symptom because each visit required the patient to answer all questions, but 
the times answered on the application vary due to skipped days and postponed surveys.  
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Table 4. Fisher’s Exact Analysis for Apple Users. The Fisher’s exact p values generated after 
comparing the responses to 8 different symptoms in clinic and on the Biewe application for Apple 
users.  
 
 
 
Table 5. Fisher’s Exact Analysis for Android Users. The Fisher’s exact p values on the 
response to eight different symptoms on the Biewe application and in the clinic for Android users.  
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Home time vs. distance travelled acted to confirm that the data sensor was 
accurate, with an R2 of -0.25 and an adjusted p value of <0.001. There was also a strong 
positive correlation between incoming and outgoing texts, with an R of 0.94 and adjusted 
p value of <0.001 (Table 6).  
Table 6. Repeated Measures Correlation Data: The “within subject” correlation data for five 
passive measures: significant locations visited, home time, distance travelled, outgoing and 
incoming texts, with false discovery rate adjusted p values.  
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Figure 3: Repeated Measures Correlations. The “within subject” correlations in the passive 
data for incoming vs. outgoing texts, and home time vs. distance travelled. Repeated measures 
correlations shows every data point collected over the course of the study for all the Android 
users in the study.  
 
Negative and positive symptoms were correlated against two passive measures, 
home time and distance travelled. Application negative symptoms scores were negatively 
correlated with the home time measure (p = 0.015, r = -0.85). Clinical negative symptom 
scores vs. home time, and application negative symptom scores vs. distance travelled, 
were found to be approaching significance with p values of 0.059 and 0.058, respectively.  
(min) 
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Figure 4: Scatter Plot Pearson Correlations. Four scatter plots showing the general trend 
agreement between the passive data measures and negative symptom scores for both the clinic 
and application. Plots A and B are graphs of the clinic and application negative symptom scores 
versus hometime in minutes per day. Plots C and D are the clinic and application negative 
symptom scores versus distance travelled. Distance travelled has arbitrary units and the scale in 
these plots is logarithmic due to the log transformation.  
 
Table 7 shows the results of all correlations done between the passive data and 
symptom scores. There were no significant results found for the positive symptom scores.  
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Table 7. Symptom Score vs. Passive Data Correlations. Pearson correlations between  
passive measures home time and distance travelled, and positive and negative symptom scores 
in both the clinic and on the application. The table includes the r and p values from the analysis.   
 
 
Negative symptom scores for clinic and application were also compared to 
bilateral anterior cingulate volumes. The application negative symptom scores were 
negatively correlated with right anterior cingulate volume (r = - 0.87, p = .036) and right 
rostral anterior cingulate volume ( r = -0.84, p = .036). The clinic negative symptom 
scores were negatively correlated with the right caudal anterior cingulate volume ( r = -
0.87, p = .04). These results are shown in Table 8 and 9.  
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Table 8. Application Negative Symptom Score Correlations. Pearson correlations between 
application negative symptom scores and various brain structures as implicated in the literature 
on schizophrenia. The table includes the r and p values, as well as the FDR corrected p value 
which adjusts for multiple comparisons.  
   
 
 
 
Table 9. Clinic Negative Symptom Score Correlations. Pearson correlations between clinic 
negative symptom scores and various brain structures as implicated in the literature on 
schizophrenia. The table includes the r and p values, as well as the FDR corrected p value which 
adjusts for multiple comparisons.    
 
 
 The positive symptom scores were correlated against a different set of brain 
volumes based on published literature. The application positive symptom scores were 
positively correlated with right fusiform volume (r = 0.88, p = 0.036), left caudate 
volume (r = 0.84, p = 0.036) and corpus callosum mid anterior volume (r = 0.84, p = 
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0.036), with sub cortical gray volume found to be trending significant post false 
discovery rate correction. The clinic positive symptom scores were positively correlated 
with right fusiform volume ( r = 0.82, p = 0.046), left caudate volume (r = 0.87, p = 
0.046) and corpus callosum mid anterior volume (r = 0.83, p = 0.046). These results are 
summarized in Tables 10 and 11.  
 
Table 10. Application Positive Symptom Score Correlations. Pearson correlations between 
application positive symptom scores and various brain structures as implicated in the literature on 
schizophrenia. The table includes the r and p values, as well as the FDR corrected p value which 
adjusts for multiple comparisons.    
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Table 11. Clinic Positive Symptom Score Correlations. Pearson correlations between clinic 
positive symptom scores and various brain structures as implicated in the literature on 
schizophrenia. The table includes the r and p values, as well as the FDR corrected p value which 
adjusts for multiple comparisons.    
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  DISCUSSION 
 The Fisher’s exact test results confirmed the hypothesis that there would be no 
discrepancies in symptom reporting on the application versus the clinic and that the 
responses in both environments would generally agree with each other. This was not 
performed on every single symptom in the study because the question sets were not 
identical, but it did account for symptoms across several different diagnoses including 
psychosis, depression and anxiety.  
The repeated measures correlation to determine within-subject correlations in the 
passive data produced two significant results. Home time vs. distance travelled was 
expected to produce a negative correlation as long as the passive data sensor was 
functioning correctly, so the result of the analysis (r = -0.25, p <0.001, Table 5) was 
reassuring. The strong positive correlation between incoming and outgoing texts (r 
= 0.94, p <0.001, Table 5) was an interesting finding because it may suggest, at least 
when it comes to the Android users in this study, that these patients are highly 
responsive to mobile communication. This may have implications for the utility of 
mobile physician – patient communication in the future, but firm conclusions are 
hard to draw from a small sample size.  
 Correlating symptom scores with the passive measures of home time and 
distance travelled yielded counterintuitive results. The negative symptom score 
versus home time correlations for both the application and clinic appeared to agree 
that patients who spent more time at home had less negative symptoms (Figure 3). 
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We hypothesized that the more withdrawn patients would be spending more time 
at home, so this result was unexpected. It could be, however, that the patients with 
more severe disease states do not have a stable home or home life and that a stable 
home life and social interaction at home leads to better outcomes, which is a 
testament to the work done by Arsova et al (2016) in which better personal and 
social functioning was observed in patients who had family support. This 
relationship would need to be pursued with a large sample size to make any 
definitive conclusions.   
In an effort to determine whether the application was more sensitive to picking up 
abnormalities in the anterior cingulate cortex, the gray matter volumes of the left and 
right caudal and rostral anterior cingulate were run against negative symptom scores. The 
application scores showed significant negative correlations to the right caudal anterior 
cingulate (r = -0.87, p = 0.03) and the right rostral anterior cingulate (r = -0.84, p = 0.03), 
while the clinic scores showed a significant negative correlation only to the right caudal 
anterior cingulate (r = -0.87, p =0.04). The review study by Bersani et al cited 9 studies 
that evidenced a link between negative symptoms and hypo-activity of the anterior 
cingulate cortex, and 7 studies that did not (Bersani et al, 2018). Furthermore, a study on 
major depressive disorder found a significant correlation between depressive symptoms 
and the rostral anterior cingulate cortex (Yoshimura et al, 2010). The right sided 
localization could be related to a study done in 2013 that showed that when compared to 
controls, the right anterior cingulate gyrus gray matter volume was significantly reduced 
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(Takayanagi et al, 2013), though the correlation here was done without a control group. 
A study done in 2005 that found a negative correlation between caudal anterior cingulate 
cortex gray matter volume and positive symptoms (Choi et al, 2005) may disagree with 
the data found here even though the relationship between positive symptoms and the 
ACC was not explored in this study.  
Positive symptom scores for the application were positively correlated with right 
fusiform gyrus gray matter volume (r = 0.87, p = 0.03), left caudate gray matter volume 
(r = 0.84, p = 0.03) and corpus callosum mid anterior gray matter volume (r = 0.84, p = 
0.03). Sub cortical gray matter volume was trending after FDR correction (r = 0.79, p = 
0.05). The clinic scores yielded similar results, though the sub cortical gray matter 
volume was not significant. A study in 2001 found that the degree of reduction in left 
caudate volume in schizophrenic patients after treatment with clozapine was significantly 
related to the extent of improvement in positive and general symptoms but not negative 
symptoms. The study also cited reports that typical antipsychotics caused an increase in 
left caudate volume, which may be an ineffective brain adaptation since large caudate 
volumes have been associated with more severe symptoms (Scheepers et al, 2001). 
Though the results could be explained by typical antipsychotic use, medication data was 
not available at the time of this study. Also of note is that when compared to controls, the 
volume of the caudate has been found to be significantly reduced (Ebdrup et al, 2010). 
Xiao et al (2013) discovered that patients with schizophrenia and their unaffected 
relatives both showed increased right fusiform gray matter volumes when compared to 
healthy controls, which they suggested may be evidence of subtle genetic anatomical 
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brain deficits. The study also noted that patients with schizophrenia and their unaffected 
relatives have shown similar functional deficits in this area. The fusiform gyrus is 
implicated in face-processing tasks, so the authors proposed that the increased volumes 
seen in both groups could be a compensatory phenomenon in response to reduced 
language-related lateralization. This compensatory mechanism may be more pronounced 
in patients with more severe disease states as defined by the presence of more positive 
symptoms. As for the corpus callosum, a 1988 study showed that the mean size of the 
anterior region of the corpus callosum was significantly greater in schizophrenics than in 
controls (Uematsu et al, 1988).  
 The results in this study have many implications for the future of clinical practice 
and mobile monitoring. We showed that the application and the clinic data generally 
agree with each other, and in some instances the application could potentially be more 
sensitive than clinical scales to brain structure alterations commonly seen in 
schizophrenia. This study also introduces passive or functional data which can provide 
objective insight into human behavior and it is clear from the results shown here that 
passive data like home time and distance travelled have the potential to be useful digital 
biomarkers. Longitudinal monitoring is also free from the recall bias and interrater 
reliability issues introduced with cross sectional clinic data, which may make it more 
reliable. If mobile monitoring is introduced in the future to function in tandem with clinic 
visits, this could lead to fewer in person visits which would reduce the financial burden 
on the patient, and increase access to care. The amount of data that this kind of 
monitoring system has the potential to produce, however, should be considered from an 
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ethics standpoint. The question is whether we really need this much data and it still 
remains to be seen whether applications like these, when used in concert with clinical 
practice, will lead to healthier patients at a lower cost. The data would have to be 
integrated into electronic medical records and it is unclear how much this would cost on a 
large scale, and if insurance would pay for the application, the data and the integration of 
the data. Patients would also have to feel comfortable with and understand the idea 
behind long term monitoring, which presents another potential future challenge due to 
privacy concerns.  
 The study had many limitations, including the small sample size, uneven gender 
distribution and the absence of a control group. In addition to these, the study would be 
very difficult to reproduce due to the novelty of applications like these. A control group 
would be useful to have in the future to perform tests such as the receiver operating 
characteristic to determine the sensitivity and specificity of the application to certain 
symptoms. The ideal control group for an analysis like this would be college students 
where the application would act as a measure of school stress levels. The small sample 
size is being addressed with the next iteration of the smart phone application, called 
LAMP (Learn, Assess, Manage, Prevent; Appendix 1a and 1b), in which 60 patients will 
be recruited for the study. Among other benefits, statistical analyses will be more 
resistant to covariate adjustments and outliers with a larger sample size. LAMP uses 
Biewe for passive data collection. 
 29 
 
 A study that was recently published in the  Journal of Psychiatric Research by a 
team at UC San Diego made a similar effort to validate the use of smartphone 
applications in the world of healthcare, and specifically to aid in the treatment of early 
psychosis. Retention and survey completion rates were promising, with 66% of 
participants remaining in the study for at least 6 months, 77% of the weekly surveys 
completed and 69% of the daily surveys completed over the course of the study. 
Participants reported that they would be open to using the application if it was part of 
their treatment (Niendam et al, 2018). The study involved a similar population of 
schizophrenic and bipolar patients, as well as a large sample size (n = 76), so it is 
reassuring that in future studies with similar patients and a large sample size, 
participation rates have the potential to be even higher than what was seen in this study 
(57% Android users, 49% Apple users).  
Future studies will want to look into the predictive validity of mobile monitoring 
applications. One of the objectives of the upcoming LAMP study is to determine reliable 
predictors of relapse which would be of great benefit to clinical practice. As the study by 
Niendam et al (2018) pointed out, it will be necessary to arrive at a consensus on how 
frequently surveys need to be completed for the application to still yield valuable 
information, since reducing the burden on the patient during long term treatments will be 
of utmost importance. This study and others like it are not meant to make a case for the 
removal of clinical scales, but rather to enhance the current state of disease assessment, 
management and prevention.  
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   APPENDIX 
Appendix 1a: Outside of the brochure created for the next iteration of the smartphone 
application, now called LAMP.  
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Appendix 1b: Inside of brochure created for the next iteration of the smartphone 
application, now called LAMP.  
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